ClinicalTrials.gg
Not yet recruitingNCT06847334Updated Feb 26, 2025

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

A Phase 3 interventional study of HLX17 and US-sourced Keytruda® in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
772
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma — 11 open to participants now, 15 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fosun Pharma.

Planned enrollment
2nd of 17
772 · median 150
Started
2025
with 3 others
Phase 3
2 of 17
1 open now
Primary completion
2027-04
later than 8 of 14 live
Registered
10th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma are open now, in 2 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, or all of them as a file.
02

Study summary

This is a multicentre, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the similarity in efficacy, safety, PK profile, and immunogenicity of HLX17 vs. Keytruda®( US- and EU-sourced) in the first-line treatment of advanced non-squamous non-small cell lung cancer.

Read the detailed description

This study includes three treatment groups. Patients will be randomly assigned at a 2:1:1 ratio to the HLX17, US-sourced Keytruda® and EU-sourced Keytruda® group to receive the treatment of IMPs in combination with Carboplatin Plus Pemetrexed until disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent form, death, unacceptable toxicity, or up to 17 cycles (whichever occurs first).

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer

Keywords

  • Keytruda biosimilar
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of stage IV inoperable to surgery or radiotherapy (AJCC 8th edition) non-squamous NSCLC.
  • Without any tumor activating EGFR mutation or ALK or ROS1 gene rearrangement.
  • Have not received prior systemic treatment for their advanced/ NSCLC.
  • At least one as assessed by IRRC based on v1.1.
  • Have a performance status of 0 or 1 on the (ECOG) Performance Status.
  • Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Subjects with NSCLC of other histopathological types, such as mixed adenosquamous carcinoma, and subjects with small cell lung cancer or neuroendocrine carcinoma.
  • Subjects with other active within 5 years or at the same time prior to screening.
  • Active central nervous system .
  • Known interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe lung function abnormalities that may impede the investigators' diagnosis and management of drug-related pulmonary toxicity.
  • Known active or suspected diseases.
  • History of immunodeficiency, including antibody positive, active ; or virus infections.
  • Have received pembrolizumab or any other immune checkpoints inhibitors (, PD-L1, CTLA4, etc.) before screening.
  • Pregnant or breastfeeding female.
  • The investigator has a clear reason to believe that participation in this study would be detrimental to the subject.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
772 participants (estimated)

Study arms

  • Experimental
    HLX17 group

    Recombinant anti-programmed death receptor-1- humanized antibody injection developed by Shanghai Henlius Biotech, Inc.

    Drug: HLX17

  • Active comparator
    US-sourced Keytruda® group

    US-sourced Keytruda

    Drug: US-sourced Keytruda®

  • Active comparator
    EU-sourced Keytruda® group

    EU-sourced Keytruda

    Drug: EU-sourced Keytruda®

Interventions

  • DrugHLX17

    HLX17 will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.

  • US-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed. After 24 weeks, all subjects in the US-Keytruda® group will receive HLX17 in combination with Pemetrexed until loss of clinical benefit or up to 1 year.

  • EU-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d)

    Time frame: Up to Day 21

  2. Area under the serum concentration-time curve within a dosing interval at steady state (AUCss)

    Time frame: Up to 1 year

  3. Best Objective Response Rate (BORR) assessed by Independent Radiology Review Committee (IRRC) based on RECIST v1.1

    Time frame: up to week 24

Secondary outcomes

  1. Maximum serum drug concentration (Cmax) after the first dose

    Time frame: Up to Day 21

  2. Trough serum drug concentration (Ctrough) after the first dose

    Time frame: Up to Day 21

  3. Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf) after the first dose

    Time frame: Up to Day 21

  4. Area under the serum concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCex) after the first dose

    Time frame: Up to Day 21

  5. Time to reach maximum serum drug concentration (Tmax) after the first dose

    Time frame: Up to Day 21

  6. Elimination half life (t1/2) after the first dose

    Time frame: Up to Day 21

  7. Volume of distribution during terminal phase (Vz) after the first dose

    Time frame: Up to Day 21

  8. Total clearance (CL) after the first dose

    Time frame: Up to Day 21

  9. Mean residence time (MRT) after the first dose

    Time frame: Up to Day 21

  10. Maximum serum drug concentration at steady-state (Cmax, ss)

    Time frame: Up to 1 year

  11. Trough serum drug concentration at steady-state (Ctrough, ss)

    Time frame: Up to 1 year

  12. Average serum drug concentration at steady-state (Cave, ss)

    Time frame: Up to 1 year

  13. Time to reach maximum serum drug concentration at steady-state (Tmax, ss)

    Time frame: Up to 1 year

  14. Elimination half life at steady-state (t1/2, ss)

    Time frame: Up to 1 year

  15. Volume of distribution at steady-state (Vss)

    Time frame: Up to 1 year

  16. Total clearance at steady-state (CLss)

    Time frame: Up to 1 year

  17. Accumulation ratio of AUC (Rac(AUC))

    Time frame: Up to 1 year

  18. Accumulation ratio of Cmax (Rac(Cmax))

    Time frame: Up to 1 year

  19. Objective response rate (ORR) assessed by IRRC (based on RECIST v1.1)

    Time frame: Up to Week 24

  20. Objective response rate (ORR) assessed by Investigator (based on RECIST v1.1)

    Time frame: Up to Week 48

  21. Duration of response (DOR) assessed by the investigator (based on RECIST v1.1)

    Time frame: Up to Week 48

  22. Time to response (TTR) assessed by the investigator (based on RECIST v1.1)

    Time frame: Up to Week 48

  23. Progression free survival (PFS) assessed by the investigator (based on RECIST v1.1)

    Time frame: Up to Week 48

  24. Progression free survival rate (PFSR) assessed by the investigator (based on RECIST v1.1)

    Time frame: Up to Week 48

  25. Overall survival (OS)

    Time frame: Up to 1 year

  26. Overall survival rate (OSR)

    Time frame: Up to 1 year

  27. Adverse events (AEs)

    Time frame: Up to Month 15

  28. Serious adverse events (SAEs)

    Time frame: Up to Month 15

  29. Incidence of anti-drug antibodies (ADAs).

    Time frame: Up to 1 year

  30. Incidence of neutralizing antibodies (NAbs).

    Time frame: Up to 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2027, 23 months later.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 23 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 26, 2025
StartEst.
Apr 27, 2025
Primary completionEst.
Apr 9, 2027
CompletionEst.
Jan 24, 2028
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847334
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Apr 27, 2025 (estimated)
Primary completion
Apr 9, 2027 (estimated)
Completion
Jan 24, 2028 (estimated)
Last update
Feb 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion